Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ: 323990)
South Korea
· Delayed Price · Currency is KRW 10,440
-280 (-2.61%)
Dec 19, 2024, 3:00 PM KST
Vaxcell-Bio Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 69.6 | 13.72 | - | - | - | - | Upgrade
|
| Cost of Revenue | 35.33 | 10.44 | 16.43 | 19.37 | 5.39 | 13.3 | Upgrade
|
| Gross Profit | 34.27 | 3.28 | -16.43 | -19.37 | -5.39 | -13.3 | Upgrade
|
| Selling, General & Admin | 7,272 | 6,171 | 5,793 | 3,811 | 2,714 | 2,857 | Upgrade
|
| Research & Development | 5,377 | 4,919 | 2,075 | 1,810 | 1,350 | 954.31 | Upgrade
|
| Other Operating Expenses | 20.16 | 20.67 | 16.62 | 6.57 | 0.44 | 1.54 | Upgrade
|
| Operating Expenses | 13,429 | 11,510 | 8,196 | 5,885 | 4,250 | 3,997 | Upgrade
|
| Operating Income | -13,394 | -11,507 | -8,213 | -5,904 | -4,255 | -4,011 | Upgrade
|
| Interest Expense | -118.96 | -43.66 | -16.68 | -26.9 | -34.9 | -717.87 | Upgrade
|
| Interest & Investment Income | 2,148 | 1,155 | 421.91 | 322.31 | 109.72 | 153.89 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.11 | -11.69 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 946.97 | 259.95 | 982.37 | 846.11 | 196.05 | 3,329 | Upgrade
|
| EBT Excluding Unusual Items | -10,422 | -10,147 | -6,825 | -4,763 | -3,984 | -1,245 | Upgrade
|
| Gain (Loss) on Sale of Investments | 11.97 | -126.84 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -22.51 | - | -0.05 | -0.25 | - | -8.58 | Upgrade
|
| Pretax Income | -10,432 | -10,274 | -6,825 | -4,763 | -3,984 | -1,254 | Upgrade
|
| Net Income | -10,432 | -10,274 | -6,825 | -4,763 | -3,984 | -1,254 | Upgrade
|
| Net Income to Common | -10,432 | -10,274 | -6,825 | -4,763 | -3,984 | -1,254 | Upgrade
|
| Shares Outstanding (Basic) | 23 | 20 | 19 | 15 | 7 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 20 | 19 | 15 | 7 | 4 | Upgrade
|
| Shares Change (YoY) | 23.04% | 2.89% | 26.09% | 122.02% | 55.35% | 23.67% | Upgrade
|
| EPS (Basic) | -444.28 | -523.77 | -358.00 | -315.00 | -585.00 | -286.00 | Upgrade
|
| EPS (Diluted) | -444.28 | -523.77 | -358.00 | -315.00 | -585.00 | -286.00 | Upgrade
|
| Free Cash Flow | -12,019 | -9,589 | -6,212 | -6,785 | -3,330 | -4,411 | Upgrade
|
| Free Cash Flow Per Share | -511.85 | -488.84 | -325.84 | -448.78 | -488.96 | -1006.28 | Upgrade
|
| Gross Margin | 49.24% | 23.90% | - | - | - | - | Upgrade
|
| Operating Margin | -19244.85% | -83851.26% | - | - | - | - | Upgrade
|
| Profit Margin | -14989.18% | -74865.84% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -17269.10% | -69872.25% | - | - | - | - | Upgrade
|
| EBITDA | -12,560 | -11,107 | -7,901 | -5,647 | -4,070 | -3,826 | Upgrade
|
| D&A For EBITDA | 834.3 | 399.68 | 311.34 | 257.25 | 185.31 | 184.73 | Upgrade
|
| EBIT | -13,394 | -11,507 | -8,213 | -5,904 | -4,255 | -4,011 | Upgrade
|
| Advertising Expenses | - | 77.55 | 38.41 | 2 | 19.76 | 12.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.